Scholarlink

Purpose <p>To describe the therapeutic efficacy of intravitreal faricimab in a refractory case of macular neovascularization (MNV) secondary to toxoplasmic chorioretinitis.</p> Methods <p>Case report.</p> Results <p>A 29-year-old woman presented with decreased vision in her right eye. She had been diagnosed with ocular toxoplasmosis four years earlier and subsequently developed secondary MNV, which was treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Previous intravitreal bevacizumab and aflibercept treatments resulted in minimal functional and anatomical improvement. On examination, best-corrected visual acuity was counting fingers at 2&#xa0;m in the right eye and 1.0 in the left. Anterior segment findings were unremarkable. Fundus evaluation of the right eye revealed a subfoveal MNV with juxtafoveal hemorrhage and subretinal fluid, confirmed by optical coherence tomography (OCT) and OCT angiography. Due to persistent activation despite prior therapy, a single intravitreal faricimab injection was administered. At three-month post-faricimab injection, visual acuity improved to 0.2, and OCT demonstrated complete resolution of subretinal fluid with a marked decrease in central macular thickness.</p> Conclusion <p>In the present case, intravitreal faricimab provided a remarkable anatomical and functional improvement in MNV secondary to toxoplasmic chorioretinitis that had been resistant to previous anti-VEGF treatments. Given its dual inhibition of VEGF-A and Angiopoetin-2, faricimab may offer an additional therapeutic advantage in managing inflammatory neovascular lesions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Successful Management of Refractory toxoplasmosis-related Macular Neovascularization with Intravitreal Faricimab

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Şefik Can İpek,
  • Seher Köksaldı,
  • Mustafa Kayabaşı,
  • Cem Yıldırım

摘要

Purpose

To describe the therapeutic efficacy of intravitreal faricimab in a refractory case of macular neovascularization (MNV) secondary to toxoplasmic chorioretinitis.

Methods

Case report.

Results

A 29-year-old woman presented with decreased vision in her right eye. She had been diagnosed with ocular toxoplasmosis four years earlier and subsequently developed secondary MNV, which was treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Previous intravitreal bevacizumab and aflibercept treatments resulted in minimal functional and anatomical improvement. On examination, best-corrected visual acuity was counting fingers at 2 m in the right eye and 1.0 in the left. Anterior segment findings were unremarkable. Fundus evaluation of the right eye revealed a subfoveal MNV with juxtafoveal hemorrhage and subretinal fluid, confirmed by optical coherence tomography (OCT) and OCT angiography. Due to persistent activation despite prior therapy, a single intravitreal faricimab injection was administered. At three-month post-faricimab injection, visual acuity improved to 0.2, and OCT demonstrated complete resolution of subretinal fluid with a marked decrease in central macular thickness.

Conclusion

In the present case, intravitreal faricimab provided a remarkable anatomical and functional improvement in MNV secondary to toxoplasmic chorioretinitis that had been resistant to previous anti-VEGF treatments. Given its dual inhibition of VEGF-A and Angiopoetin-2, faricimab may offer an additional therapeutic advantage in managing inflammatory neovascular lesions.